- Home
- NBIX vs TECK Comparison
NBIX vs TECK Comparison
Compare NBIX & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- TECK
- Stock Information
- Founded
- NBIX 1992
- TECK 1913
- Country
- NBIX United States
- TECK Canada
- Employees
- NBIX N/A
- TECK N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- TECK
- Sector
- NBIX Health Care
- TECK
- Exchange
- NBIX Nasdaq
- TECK Nasdaq
- Market Cap
- NBIX 13.2B
- TECK 15.5B
- IPO Year
- NBIX 1996
- TECK N/A
- Fundamental
- Price
- NBIX $139.60
- TECK $34.20
- Analyst Decision
- NBIX Strong Buy
- TECK Buy
- Analyst Count
- NBIX 18
- TECK 9
- Target Price
- NBIX $160.94
- TECK $60.11
- AVG Volume (30 Days)
- NBIX 782.5K
- TECK 2.9M
- Earning Date
- NBIX 10-29-2025
- TECK 10-23-2025
- Dividend Yield
- NBIX N/A
- TECK 2.12%
- EPS Growth
- NBIX 2.97
- TECK N/A
- EPS
- NBIX 3.39
- TECK 0.40
- Revenue
- NBIX $2,509,900,000.00
- TECK $7,300,602,697.00
- Revenue This Year
- NBIX $20.66
- TECK $13.66
- Revenue Next Year
- NBIX $14.64
- TECK $10.82
- P/E Ratio
- NBIX $40.91
- TECK $86.40
- Revenue Growth
- NBIX 18.42
- TECK 37.28
- 52 Week Low
- NBIX $84.23
- TECK $28.32
- 52 Week High
- NBIX $154.61
- TECK $54.13
- Technical
- Relative Strength Index (RSI)
- NBIX 68.09
- TECK 54.33
- Support Level
- NBIX $133.62
- TECK $32.36
- Resistance Level
- NBIX $137.03
- TECK $34.06
- Average True Range (ATR)
- NBIX 2.36
- TECK 0.73
- MACD
- NBIX 0.83
- TECK 0.42
- Stochastic Oscillator
- NBIX 97.44
- TECK 94.15
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024.